company background image
ABS

Arterra BioscienceBIT:ABS Stock Report

Last Price

€2.90

Market Cap

€19.1m

7D

-2.7%

1Y

-6.8%

Updated

19 Jan, 2022

Data

Company Financials
ABS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

ABS Stock Overview

Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions.

Price History & Performance

Summary of all time highs, changes and price drops for Arterra Bioscience
Historical stock prices
Current Share Price€2.90
52 Week High€4.40
52 Week Low€2.72
Beta1.37
1 Month Change1.40%
3 Month Change-18.99%
1 Year Change-6.75%
3 Year Changen/a
5 Year Changen/a
Change since IPO-14.99%

Recent News & Updates

May 27
Estimating The Intrinsic Value Of Arterra Bioscience S.p.A. (BIT:ABS)

Estimating The Intrinsic Value Of Arterra Bioscience S.p.A. (BIT:ABS)

Today we will run through one way of estimating the intrinsic value of Arterra Bioscience S.p.A. ( BIT:ABS ) by taking...

Shareholder Returns

ABSIT BiotechsIT Market
7D-2.7%-4.1%-0.9%
1Y-6.8%-19.9%19.3%

Return vs Industry: ABS exceeded the Italian Biotechs industry which returned -19.3% over the past year.

Return vs Market: ABS underperformed the Italian Market which returned 20.3% over the past year.

Price Volatility

Is ABS's price volatile compared to industry and market?
ABS volatility
ABS Average Weekly Movement3.4%
Biotechs Industry Average Movement7.5%
Market Average Movement4.3%
10% most volatile stocks in IT Market7.2%
10% least volatile stocks in IT Market2.7%

Stable Share Price: ABS is not significantly more volatile than the rest of Italian stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ABS's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200329Maria Coluccihttps://www.arterrabio.it

Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions. It develops technological platforms, extraction processes, and raw materials for use in the cosmetics, agriculture, and nutraceutics sectors. The company was founded in 2003 and is based in Naples, Italy.

Arterra Bioscience Fundamentals Summary

How do Arterra Bioscience's earnings and revenue compare to its market cap?
ABS fundamental statistics
Market Cap€19.07m
Earnings (TTM)€1.15m
Revenue (TTM)€4.38m

16.5x

P/E Ratio

4.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABS income statement (TTM)
Revenue€4.38m
Cost of Revenue€1.36m
Gross Profit€3.02m
Expenses€1.86m
Earnings€1.15m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.18
Gross Margin68.85%
Net Profit Margin26.37%
Debt/Equity Ratio8.7%

How did ABS perform over the long term?

See historical performance and comparison

Valuation

Is Arterra Bioscience undervalued compared to its fair value and its price relative to the market?

16.51x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABS is good value based on its PE Ratio (16.5x) compared to the European Biotechs industry average (27.9x).

PE vs Market: ABS is good value based on its PE Ratio (16.5x) compared to the Italian market (19.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABS is good value based on its PB Ratio (2.2x) compared to the XE Biotechs industry average (3.9x).


Future Growth

How is Arterra Bioscience forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Arterra Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Arterra Bioscience performed over the past 5 years?

1.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABS has high quality earnings.

Growing Profit Margin: ABS's current net profit margins (26.4%) are higher than last year (14.5%).


Past Earnings Growth Analysis

Earnings Trend: ABS's earnings have grown by 1.8% per year over the past 5 years.

Accelerating Growth: ABS's earnings growth over the past year (101.4%) exceeds its 5-year average (1.8% per year).

Earnings vs Industry: ABS earnings growth over the past year (101.4%) exceeded the Biotechs industry 50.7%.


Return on Equity

High ROE: ABS's Return on Equity (13.5%) is considered low.


Financial Health

How is Arterra Bioscience's financial position?


Financial Position Analysis

Short Term Liabilities: ABS's short term assets (€8.0M) exceed its short term liabilities (€664.5K).

Long Term Liabilities: ABS's short term assets (€8.0M) exceed its long term liabilities (€1.7M).


Debt to Equity History and Analysis

Debt Level: ABS has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ABS's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: ABS's debt is well covered by operating cash flow (64.3%).

Interest Coverage: ABS's interest payments on its debt are well covered by EBIT (173.5x coverage).


Balance Sheet


Dividend

What is Arterra Bioscience current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABS's dividend in 3 years as they are not forecast to pay a notable one for the Italian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Maria Colucci (61 yo)

no data

Tenure

Ms. Maria Gabriella Colucci serves as Chairman of the Board of Directors and Chief Executive Officer at Arterra Bioscience S.p.A.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Arterra Bioscience S.p.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Arterra Bioscience S.p.A.
  • Ticker: ABS
  • Exchange: BIT
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €19.067m
  • Shares outstanding: 6.57m
  • Website: https://www.arterrabio.it

Number of Employees


Location

  • Arterra Bioscience S.p.A.
  • via Benedetto Brin, 69
  • Napoli
  • Naples
  • 80142
  • Italy

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 21:24
End of Day Share Price2022/01/19 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.